On a year-to-date basis, the Polaris Global Equity Composite is up 12.84% (net of fees), handily outperforming both the MSCI ...

If we don’t incentivize continued investments in drug research and development, we’ll lose out on new therapies that don’t ...

ADI shares flashed a Golden Cross pattern on July 1, when the 50-day moving average crossed above the 200-day, a classic ...

Democrats aren't rushing to play ball with Republicans on a bipartisan health care package after passage of the president's ...

A number of healthcare stocks fell in the afternoon session after several negative developments weighed on the sector.

Prescription drugs account for 15% of health care costs. Yet, they’re our best defense against the chronic diseases that ...

President Donald Trump’s “big, beautiful bill,” which he signed into law earlier this month, includes major wins for business ...

The next round of Medicare's historic drug price negotiations could save billions for seniors taking medications like Ozempic ...

The direct-to-consumer (DTC) platform – called Eliquis 360 Support – will offer Eliquis (apixaban) to patients who pay for ...

As the Trump administration begins to make its mark on the Medicare drug price negotiation program, litigation over the ...

Bristol Myers and Pfizer said on Thursday they will start selling their blockbuster blood thinner, Eliquis, directly to ...

Drug development is a decade-long, costly process replete with failures. If we don’t incentivize investments in research and ...